

THERAPEUTIC AREA	PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
Antiallergics	Desloratadine	Allergy	√	EU-CN DMF
	Loratadine^P	Allergy	√	JP DMF
Antiarrhythmics	Dronedarone^P	Atrial fibrillation & general arrhythmia		DMF
Antiasthmatics, COPD and respiratory diseases	Arformoterol tartrate^P polymorph A and D	COPD		US-CN DMF
	Formoterol fumarate	Asthma and COPD	√	CEP/US-JP-KR-CN DMF
	Glycopyrronium bromide^P	COPD	√	CEP/ US DMF
	Montelukast sodium^P	Asthma, allergic & seasonal rhinitis		EU-JP DMF
	Salbutamol sulfate	Asthma and COPD	√	
	Salmeterol xinafoate^P	Asthma and COPD	√	CEP/ US-CN DMF
Antiemetics	Granisetron base^P	Emesis		US DMF
	Granisetron hydrochloride^P	Emesis		CEP/ US-JP-KR DMF
	Ondansetron base^P	Emesis	√	EU-US DMF
	Ondansetron hydrochloride^P	Emesis	√	CEP/US DMF
Antifungals	Fluconazol^P	Antifungal		CEP/US-KR DMF
Antihypertensive	Carvedilol^P	Hypertension, angina, heart failure		JP DMF
	Enalapril maleate^P	Hypertension		CEP/KR DMF
	Imidapril	Hypertension		EU DMF
	Nitrendipine	Hypertension	√	CEP/DMF
Antimigrainics	Eletriptan HBr^P	Migraine	√	JP DMF
	Rizatriptan benzoate^P	Migraine	√	EU-US DMF
	Zolmitriptan^P	Migraine	√	EU-US DMF
Antipsychotics	Asenapine maleate^P	Schizophrenia and acute mania	√	
	Clomethiazole	Insomnia		EU DMF
	Olanzapine^P	Schizophrenia, psychosis		EU-US- DMF
	Quetiapine hemifumarate^P	Schizophrenia, psychosis		JP-KR DMF
	Risperidone^P	Schizophrenia, psychosis	√	CEP/US-KR DMF
Antithrombotics	Prasugrel base^P	Prophylaxis and therapy of thrombosis		EU DMF
Spasmolytic	Otilonium bromide	Irritable bowel syndrome		EU DMF

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.